MA26875A1 - Composes azapolycycliques a noyau aryle condensé - Google Patents
Composes azapolycycliques a noyau aryle condenséInfo
- Publication number
- MA26875A1 MA26875A1 MA26775A MA26775A MA26875A1 MA 26875 A1 MA26875 A1 MA 26875A1 MA 26775 A MA26775 A MA 26775A MA 26775 A MA26775 A MA 26775A MA 26875 A1 MA26875 A1 MA 26875A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- condensed aryl
- formula
- azapolycyclic
- azapolycyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/514,002 US6605610B1 (en) | 1997-12-31 | 2000-02-25 | Aryl fused azapolycyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26875A1 true MA26875A1 (fr) | 2004-12-20 |
Family
ID=24045406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA26775A MA26875A1 (fr) | 2000-02-25 | 2002-08-13 | Composes azapolycycliques a noyau aryle condensé |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US6605610B1 (ref) |
| EP (2) | EP1619192B1 (ref) |
| JP (1) | JP2003524002A (ref) |
| KR (1) | KR100537976B1 (ref) |
| CN (1) | CN1263745C (ref) |
| AP (1) | AP1860A (ref) |
| AT (2) | ATE328872T1 (ref) |
| AU (2) | AU784081B2 (ref) |
| BG (1) | BG65891B1 (ref) |
| BR (1) | BR0108610A (ref) |
| CA (1) | CA2401229C (ref) |
| CR (1) | CR6726A (ref) |
| CU (1) | CU23148A3 (ref) |
| CY (1) | CY1105301T1 (ref) |
| CZ (1) | CZ303203B6 (ref) |
| DE (2) | DE60120366T2 (ref) |
| DK (2) | DK1619192T3 (ref) |
| DZ (1) | DZ3328A1 (ref) |
| EA (1) | EA005316B1 (ref) |
| EE (1) | EE200200475A (ref) |
| ES (2) | ES2263640T3 (ref) |
| GE (1) | GEP20053454B (ref) |
| HR (1) | HRP20020700A2 (ref) |
| HU (1) | HU229482B1 (ref) |
| IL (2) | IL150639A0 (ref) |
| IS (1) | IS2293B (ref) |
| MA (1) | MA26875A1 (ref) |
| MX (1) | MXPA02008311A (ref) |
| NO (1) | NO323608B1 (ref) |
| NZ (1) | NZ519973A (ref) |
| OA (1) | OA12181A (ref) |
| PL (1) | PL365163A1 (ref) |
| PT (1) | PT1259489E (ref) |
| RS (1) | RS51123B (ref) |
| SI (1) | SI1259489T1 (ref) |
| SK (1) | SK12042002A3 (ref) |
| UA (1) | UA74813C2 (ref) |
| WO (1) | WO2001062736A1 (ref) |
| ZA (1) | ZA200206768B (ref) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1044189E (pt) * | 1997-12-31 | 2008-04-22 | Pfizer Prod Inc | Compostos azapolicíclicos condensados com arilo |
| PT1383733E (pt) * | 2001-04-20 | 2008-04-15 | Pfizer Prod Inc | Processo para a preparação de indenos 1,3-substituídos e compostos azapolicíclicos fundidos com arilo |
| PL370549A1 (en) * | 2001-10-31 | 2005-05-30 | Pfizer Products Inc. | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| DE60228478D1 (de) * | 2001-11-30 | 2008-10-02 | Pfizer Prod Inc | Aryl-annellierte azapolyzyklische verbindungen |
| MXPA04003807A (es) * | 2001-11-30 | 2004-07-30 | Pfizer Prod Inc | Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno. |
| KR101228376B1 (ko) | 2002-07-18 | 2013-01-31 | 사이토스 바이오테크놀로지 아게 | 합텐-캐리어 컨쥬게이트 및 그의 용도 |
| WO2004037850A2 (en) * | 2002-10-22 | 2004-05-06 | Millipore Corporation | Multi-sided immersion formation of composite structures and method |
| RU2284319C2 (ru) * | 2002-11-25 | 2006-09-27 | Пфайзер Продактс Инк. | Усовершенствованный способ получения 1,3-замещенных инденов |
| CA2513293A1 (en) * | 2003-01-15 | 2004-07-29 | Pfizer Products Inc. | Process for the preparation of aryl fused polycyclic lactams |
| EP1633358A1 (en) * | 2003-05-20 | 2006-03-15 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
| DK1638971T3 (da) * | 2003-06-04 | 2008-10-27 | Pfizer Prod Inc | Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan |
| MXPA06000892A (es) * | 2003-07-21 | 2006-03-30 | Pfizer Prod Inc | Compuestos azapoliciclicos arilo fusionados. |
| US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| MXPA06004088A (es) * | 2003-10-14 | 2006-06-27 | Xenoport Inc | Forma cristalina de un analogo del acido gamma-aminobutirico. |
| CA2549638A1 (en) * | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
| ATE411994T1 (de) * | 2005-02-24 | 2008-11-15 | Pfizer Prod Inc | Herstellung eines substituierten chinoxalins von hoher reinheit |
| CN101420939A (zh) * | 2006-04-24 | 2009-04-29 | 辉瑞产品公司 | 用于药物递送装置的不对称膜 |
| EP2086977A2 (en) * | 2006-11-09 | 2009-08-12 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
| US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| US20090062257A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched varenicline |
| WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
| WO2009065872A2 (en) * | 2007-11-20 | 2009-05-28 | Medichem, S.A. | Improved processes for the synthesis of varenicline l-tartrate |
| CN102026995B (zh) | 2007-12-07 | 2014-10-29 | Abbvie德国有限责任两合公司 | 5，6-二取代的羟吲哚衍生物和其用途 |
| US8703774B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| CN101952276B (zh) * | 2007-12-07 | 2014-10-22 | Abbvie德国有限责任两合公司 | 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途 |
| EP2231643B1 (de) | 2007-12-07 | 2012-10-31 | Abbott GmbH & Co. KG | Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| EP2271344A4 (en) | 2008-03-31 | 2011-04-27 | Univ South Florida | METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE |
| US8039620B2 (en) * | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
| WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| EP2334679A1 (en) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
| RU2011137419A (ru) * | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| US8178537B2 (en) * | 2009-06-22 | 2012-05-15 | Teva Pharmaceutical Industries Ltd. | Solid state forms of varenicline salts and processes for preparation thereof |
| EP3590498A4 (en) | 2017-03-03 | 2020-12-16 | CTC Bio, Inc. | PREPARATION, INCLUDING AN INCLUSION COMPLEX OF VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREFOR, FOR ORAL ADMINISTRATION |
| AU2020416203A1 (en) * | 2020-01-03 | 2022-06-16 | Blue Oak Pharmaceuticals, Inc. | Compounds and compositions for treating CNS disorders |
| CN115322105A (zh) * | 2021-05-11 | 2022-11-11 | 江苏润安制药有限公司 | 一种合成艾拉莫德关键中间体的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471503A (en) | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
| PT1044189E (pt) * | 1997-12-31 | 2008-04-22 | Pfizer Prod Inc | Compostos azapolicíclicos condensados com arilo |
| EP0955301A3 (en) | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| WO1999055680A1 (en) | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| EP1147112B1 (en) * | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| FR2788982B1 (fr) * | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| JP2004532826A (ja) * | 2001-03-19 | 2004-10-28 | スローン−ケッタリング インスティトゥート フォー カンサー リサーチ | （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用 |
| MXPA06000892A (es) * | 2003-07-21 | 2006-03-30 | Pfizer Prod Inc | Compuestos azapoliciclicos arilo fusionados. |
| US8123947B2 (en) | 2007-10-22 | 2012-02-28 | Baxter International Inc. | Priming and air removal systems and methods for dialysis |
-
2000
- 2000-02-25 US US09/514,002 patent/US6605610B1/en not_active Expired - Fee Related
-
2001
- 2001-02-08 DE DE60120366T patent/DE60120366T2/de not_active Expired - Lifetime
- 2001-02-08 EA EA200200716A patent/EA005316B1/ru not_active IP Right Cessation
- 2001-02-08 JP JP2001562518A patent/JP2003524002A/ja active Pending
- 2001-02-08 SK SK1204-2002A patent/SK12042002A3/sk not_active Application Discontinuation
- 2001-02-08 ES ES01953630T patent/ES2263640T3/es not_active Expired - Lifetime
- 2001-02-08 DK DK05106835.1T patent/DK1619192T3/da active
- 2001-02-08 EP EP05106835A patent/EP1619192B1/en not_active Expired - Lifetime
- 2001-02-08 GE GE4911A patent/GEP20053454B/en unknown
- 2001-02-08 MX MXPA02008311A patent/MXPA02008311A/es active IP Right Grant
- 2001-02-08 ES ES05106835T patent/ES2336800T3/es not_active Expired - Lifetime
- 2001-02-08 KR KR10-2002-7011140A patent/KR100537976B1/ko not_active Expired - Fee Related
- 2001-02-08 AT AT01953630T patent/ATE328872T1/de active
- 2001-02-08 AU AU28748/01A patent/AU784081B2/en not_active Ceased
- 2001-02-08 DE DE60140965T patent/DE60140965D1/de not_active Expired - Lifetime
- 2001-02-08 WO PCT/IB2001/000153 patent/WO2001062736A1/en not_active Ceased
- 2001-02-08 AP APAP/P/2002/002604A patent/AP1860A/en active
- 2001-02-08 AT AT05106835T patent/ATE453643T1/de not_active IP Right Cessation
- 2001-02-08 DK DK01953630T patent/DK1259489T3/da active
- 2001-02-08 PL PL01365163A patent/PL365163A1/xx not_active Application Discontinuation
- 2001-02-08 BR BR0108610-3A patent/BR0108610A/pt not_active Application Discontinuation
- 2001-02-08 HR HRP20020700 patent/HRP20020700A2/hr not_active Application Discontinuation
- 2001-02-08 CZ CZ20022778A patent/CZ303203B6/cs not_active IP Right Cessation
- 2001-02-08 PT PT01953630T patent/PT1259489E/pt unknown
- 2001-02-08 OA OA1200200256A patent/OA12181A/en unknown
- 2001-02-08 EP EP01953630A patent/EP1259489B1/en not_active Expired - Lifetime
- 2001-02-08 IL IL15063901A patent/IL150639A0/xx active IP Right Grant
- 2001-02-08 HU HU0204580A patent/HU229482B1/hu not_active IP Right Cessation
- 2001-02-08 CN CNB018055737A patent/CN1263745C/zh not_active Expired - Fee Related
- 2001-02-08 RS YUP-596/02A patent/RS51123B/sr unknown
- 2001-02-08 DZ DZ013328A patent/DZ3328A1/fr active
- 2001-02-08 NZ NZ519973A patent/NZ519973A/en not_active IP Right Cessation
- 2001-02-08 SI SI200130584T patent/SI1259489T1/sl unknown
- 2001-02-08 CA CA002401229A patent/CA2401229C/en not_active Expired - Fee Related
- 2001-02-08 EE EEP200200475A patent/EE200200475A/xx unknown
- 2001-08-02 UA UA2002075792A patent/UA74813C2/uk unknown
-
2002
- 2002-07-05 IS IS6459A patent/IS2293B/is unknown
- 2002-07-05 BG BG106908A patent/BG65891B1/bg unknown
- 2002-07-08 IL IL150639A patent/IL150639A/en not_active IP Right Cessation
- 2002-08-09 CR CR6726A patent/CR6726A/es unknown
- 2002-08-13 MA MA26775A patent/MA26875A1/fr unknown
- 2002-08-21 CU CU177A patent/CU23148A3/es not_active IP Right Cessation
- 2002-08-22 ZA ZA200206768A patent/ZA200206768B/xx unknown
- 2002-08-23 NO NO20024042A patent/NO323608B1/no not_active IP Right Cessation
-
2003
- 2003-01-03 US US10/336,532 patent/US7144882B2/en not_active Expired - Fee Related
- 2003-01-03 US US10/336,508 patent/US7205300B2/en not_active Expired - Fee Related
-
2005
- 2005-11-18 AU AU2005234671A patent/AU2005234671B2/en not_active Ceased
-
2006
- 2006-07-21 CY CY20061101011T patent/CY1105301T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| TN2009000471A1 (fr) | Composes amino-heterocycliques | |
| TNSN98237A1 (fr) | Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA27439A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA26689A1 (fr) | Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA27138A1 (fr) | Composes heteroaryliques condenses a substituant azabicyclique pour le traitement d'une maladie | |
| TNSN04137A1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
| MA27451A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| MA31800B1 (fr) | Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique | |
| MA26864A1 (fr) | Antagonistes du facteur de liberation de corticotrophine. | |
| MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
| TNSN06200A1 (fr) | Derives de quinoleine nouveaux | |
| TNSN97044A1 (fr) | Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| MA26690A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
| TNSN07366A1 (fr) | Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie | |
| TNSN98151A1 (fr) | Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole. | |
| MA27197A1 (fr) | Sels de tolterodine | |
| MA26953A1 (fr) | Derives de pipérazine pontés. | |
| FR2716883B1 (fr) | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| EP0879054B1 (fr) | Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues |